{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:43:32Z","timestamp":1791855812950,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Minimal change disease (MCD) is a major cause of nephrotic syndrome (NS) in children and a minority of adults. The higher tendency to relapse put patients at risk for prolonged exposure to steroids and other immunosuppressive agents. B cell depletion with rituximab (RTX) may be beneficial to the treatment and prevention of frequently relapsing MCD. Therefore, this study aimed to verify the therapeutic\/preventive effects of low-dose RTX on the relapse in adult with MCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 33 adult patients were selected for the study, including 22 patients with relapsing MCD in relapse treatment group who were treated with low-dose RTX (200\u00a0mg per week \u00d7 4 following by 200\u00a0mg every 6 months) and 11 patients in relapse prevention group with complete remission (CR) after steroid therapy were treated with RTX (200\u00a0mg \u00d71 every 6 months) for preventing the relapse of MCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 22 patients with MCD in relapse treatment group, there were 21 cases (95.45%) of remission [2 (9.09%) partial remission (PR), 19 (86.36%) CR], 1 (4.56%) no remission (NR) and 20 (90.90%) relapse-free. The Median duration of sustained remission was 16.3 months (3, 23.5 months, inter quartile range (IQR)). 11 patients in the relapse prevention group during a follow-up of 12 months (9\u201331 months) had no relapse. The average dose of prednisone in two groups after RTX treatment was significantly lower than before treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results of this study suggested low-dose RTX can significantly reduce relapse rate and steroid dose in adults with MCD with fewer side effects. Low-dose RTX regimens may be beneficial for the treatment of relapsing MCD in adults and may be the preferred regimen for patients at high risk for the development of adverse events from corticosteroids.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-023-03092-7","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T10:03:25Z","timestamp":1682503405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of low-dose rituximab in minimal change disease and prevention of relapse"],"prefix":"10.1186","volume":"24","author":[{"given":"Jian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"3092_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0272-6386(87)80170-1","volume":"10","author":"JS Cameron","year":"1987","unstructured":"Cameron JS. The nephrotic syndrome and its complications. Am J Kidney Dis. 1987;10:157\u201371.","journal-title":"Am J Kidney Dis"},{"key":"3092_CR2","doi-asserted-by":"crossref","unstructured":"Avner E, Harmon W, Niaudet P, Yoshikawa N, Emma F, Goldstein S. Idiopathic Nephrotic Syndrome in Children: Clinical Aspects. Pediatric Nephrology, 7th Ed. 2016:pp\u00a02730.","DOI":"10.1007\/978-3-662-43596-0"},{"key":"3092_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/ki.1990.175","volume":"38","author":"A Fogo","year":"1990","unstructured":"Fogo A, Hawkins EP, Berry PL, Glick AD, Chiang ML, MacDonell RC Jr, et al. Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int. 1990;38:115\u201323.","journal-title":"Kidney Int"},{"key":"3092_CR4","unstructured":"Schnaper H, Robson A, Kopp J. Nephrotic syndrome: Minimal change nephropathy, focal segmental glomerulosclerosis, and collapsing glomerulopathy. In: Diseases of the Kidney and Urinary Tract, 8th ed. 2007:p.1585."},{"key":"3092_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/jemt.10082","volume":"57","author":"I Shirato","year":"2002","unstructured":"Shirato I. Podocyte process effacement in vivo. Microsc Res Tech. 2002;57:241\u20136.","journal-title":"Microsc Res Tech"},{"key":"3092_CR6","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00467-011-1947-1","volume":"27","author":"V Elie","year":"2012","unstructured":"Elie V, Fakhoury M, Desch\u00eanes G, Jacqz-Aigrain E. Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives. Pediatr Nephrol. 2012;27:1249\u201356.","journal-title":"Pediatr Nephrol"},{"key":"3092_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","volume":"2","author":"RJ Shalhoub","year":"1974","unstructured":"Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;2:556\u201360.","journal-title":"Lancet"},{"key":"3092_CR8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nrneph.2016.147","volume":"12","author":"RJ Maas","year":"2016","unstructured":"Maas RJ, Deegens JK, Smeets B, Moeller MJ, Wetzels JF. Minimal change disease and idiopathic FSGS: manifestations of the same disease. Nat Rev Nephrol. 2016;12:768\u201376.","journal-title":"Nat Rev Nephrol"},{"issue":"Suppl 4","key":"3092_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/nep.13463","volume":"23","author":"Y Liu","year":"2018","unstructured":"Liu Y, Shi Y, Ren R, Xie J, Wang W, Chen N. Advanced therapeutics in focal and segmental glomerulosclerosis. Nephrol (Carlton). 2018;23(Suppl 4):57\u201361.","journal-title":"Nephrol (Carlton)"},{"key":"3092_CR10","doi-asserted-by":"publisher","first-page":"823204","DOI":"10.3389\/fimmu.2022.823204","volume":"13","author":"M Colucci","year":"2022","unstructured":"Colucci M, et al. B-Cell dysregulation in idiopathic nephrotic syndrome: what we know and what we need to Discover. Front Immunol. 2022;13:823204.","journal-title":"Front Immunol"},{"key":"3092_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2215\/CJN.01920219","volume":"14","author":"SM Korbet","year":"2019","unstructured":"Korbet SM, Whittier WL. Management of adult minimal change disease. Clin J Am Soc Nephrol. 2019;14:911\u20133.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3092_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, et al. Rituximab for severe membranous nephropathy: a 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol. 2017;28:348\u201358.","journal-title":"J Am Soc Nephrol"},{"key":"3092_CR13","first-page":"150","volume":"15","author":"O Gheith","year":"2017","unstructured":"Gheith O, Al-Otaibi T, Halim MA, Mahmoud T, Nair P, Monem MA, et al. Early Versus Late Acute antibody-mediated rejection among renal transplant recipients in terms of response to Rituximab Therapy: a single Center experience. Exp Clin Transplant. 2017;15:150\u20135.","journal-title":"Exp Clin Transplant"},{"key":"3092_CR14","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Auma\u00eetre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771\u201380.","journal-title":"N Engl J Med"},{"key":"3092_CR15","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","volume":"360","author":"G Remuzzi","year":"2002","unstructured":"Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet. 2002;360:923\u20134.","journal-title":"Lancet"},{"key":"3092_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"Kidney Disease Improving Global Outcomes","year":"2012","unstructured":"Kidney Disease Improving Global Outcomes. KDIGO Clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:1\u2013274.","journal-title":"Kidney Int Suppl"},{"key":"3092_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1046\/j.1365-2567.2002.01495.x","volume":"107","author":"JP Deans","year":"2002","unstructured":"Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology. 2002;107:176\u201382.","journal-title":"Immunology"},{"key":"3092_CR18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1517\/14656566.8.7.913","volume":"8","author":"KK Sureshkumar","year":"2007","unstructured":"Sureshkumar KK, Hussain SM, Carpenter BJ, Sandroni SE, Marcus RJ. Antibody-mediated rejection following renal transplantation. Expert Opin Pharmacother. 2007;8:913\u201321.","journal-title":"Expert Opin Pharmacother"},{"key":"3092_CR19","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1093\/oxfordjournals.ndt.a027136","volume":"11","author":"SK Mak","year":"1996","unstructured":"Mak SK, Short CD, Mallick NP. Long-term outcome of adult-onset minimal-change nephropathy. Nephrol Dial Transplant. 1996;11:2192\u2013201.","journal-title":"Nephrol Dial Transplant"},{"key":"3092_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1053\/ajkd.2002.31400","volume":"39","author":"M Nakayama","year":"2002","unstructured":"Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis. 2002;39:503\u201312.","journal-title":"Am J Kidney Dis"},{"key":"3092_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2215\/CJN.03531006","volume":"2","author":"M Waldman","year":"2007","unstructured":"Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2:445\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3092_CR22","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1681\/ASN.2012070734","volume":"24","author":"J Hogan","year":"2013","unstructured":"Hogan J, Radhakrishnan J. The treatment of minimal change disease in adults. J Am Soc Nephrol. 2013;24:702\u201311.","journal-title":"J Am Soc Nephrol"},{"key":"3092_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2174\/157340606777724068","volume":"2","author":"DS Goumenos","year":"2006","unstructured":"Goumenos DS, Kalliakmani P, Tsakas S, Savidaki I, Vlachojannis JG. Cyclosporin-A in the treatment of nephrotic syndrome: the importance of monitoring C0 (trough) and C2 (two hours after its administration) blood levels. Med Chem. 2006;2:391\u20133.","journal-title":"Med Chem"},{"key":"3092_CR24","first-page":"447","volume":"44","author":"M Koike","year":"2002","unstructured":"Koike M, Honda K, Tsukada M, Itabashi M, Suzuki K, Uchida K, et al. [Low-dose cyclosporin therapy combined with prednisolone for relapsing minimal change nephrotic syndrome in adults]. Nihon Jinzo Gakkai Shi. 2002;44:447\u201352.","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"3092_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2215\/CJN.06180519","volume":"15","author":"NR Medjeral-Thomas","year":"2020","unstructured":"Medjeral-Thomas NR, Lawrence C, Condon M, Sood B, Warwicker P, Brown H, et al. Randomized, controlled trial of Tacrolimus and Prednisolone Monotherapy for adults with De Novo Minimal Change Disease: a Multicenter, Randomized, Controlled Trial. Clin J Am Soc Nephrol. 2020;15:209\u201318.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3092_CR26","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1093\/ndt\/gfi274","volume":"21","author":"MD Sinha","year":"2006","unstructured":"Sinha MD, MacLeod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant. 2006;21:1848\u201354.","journal-title":"Nephrol Dial Transplant"},{"key":"3092_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2009.02.018","volume":"54","author":"X Li","year":"2009","unstructured":"Li X, Li H, Ye H, Li Q, He X, Zhang X, et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis. 2009;54:51\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 6","key":"3092_CR28","first-page":"vi79","volume":"18","author":"A Meyrier","year":"2003","unstructured":"Meyrier A. Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol Dial Transplant. 2003;18(Suppl 6):vi79\u201386.","journal-title":"Nephrol Dial Transplant"},{"key":"3092_CR29","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3:85ra46.","journal-title":"Sci Transl Med"},{"key":"3092_CR30","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/ki.2012.444","volume":"83","author":"H Munyentwali","year":"2013","unstructured":"Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013;83:511\u20136.","journal-title":"Kidney Int"},{"key":"3092_CR31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nrneph.2012.289","volume":"9","author":"A Sinha","year":"2013","unstructured":"Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients\u2019 management. Nat Rev Nephrol. 2013;9:154\u201369.","journal-title":"Nat Rev Nephrol"},{"key":"3092_CR32","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ckj\/sfaa191","volume":"14","author":"C Xue","year":"2021","unstructured":"Xue C, Yang B, Xu J, Zhou C, Zhang L, Gao X, et al. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. Clin Kidney J. 2021;14:1042\u201354.","journal-title":"Clin Kidney J"},{"key":"3092_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000187472","volume":"65","author":"J Laurent","year":"1993","unstructured":"Laurent J, Philippon C, Lagrue G, et al. Proteinuria selectivity index\u2013prognostic value in lipoid nephrosis and related diseases. Nephron. 1993;65:185\u20139.","journal-title":"Nephron"},{"key":"3092_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0009-8981(00)00235-7","volume":"297","author":"J Tencer","year":"2000","unstructured":"Tencer J, Bakoush O, Torffvit O. Diagnostic and prognostic significance of proteinuria selectivity index in glomerular diseases. Clin Chim Acta. 2000;297:73\u201383.","journal-title":"Clin Chim Acta"},{"key":"3092_CR35","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1046\/j.1523-1755.2000.00334.x","volume":"58","author":"C Bazzi","year":"2000","unstructured":"Bazzi C, Petrini C, Rizza V, et al. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int. 2000;58:1732\u2013741.","journal-title":"Kidney Int"},{"issue":"4","key":"3092_CR36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/ndt\/gfab323","volume":"37","author":"M Allinovi","year":"2022","unstructured":"Allinovi M, et al. Proteinuria selectivity index predicts response to rituximab in adults with minimal change disease and focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2022;37(4):789\u201391.","journal-title":"Nephrol Dial Transplant"},{"key":"3092_CR37","first-page":"369","volume":"22","author":"C Legeay","year":"2017","unstructured":"Legeay C, Bittencourt H, Haddad E, Spiesser-Robelet L, Th\u00e9pot-Seegers V, Therrien R. A retrospective study on infusion-related reactions to Rituximab in a heterogeneous Pediatric Population. J Pediatr Pharmacol Ther. 2017;22:369\u201374.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"3092_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s11096-017-0429-3","volume":"39","author":"T Hayama","year":"2017","unstructured":"Hayama T, Miura K, Uchiike A, Nakagawa M, Tsutsumi D, Sakagami M, et al. A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas. Int J Clin Pharm. 2017;39:380\u20135.","journal-title":"Int J Clin Pharm"},{"key":"3092_CR39","doi-asserted-by":"publisher","first-page":"102671","DOI":"10.1016\/j.autrev.2020.102671","volume":"19","author":"P Gauckler","year":"2020","unstructured":"Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, et al. Rituximab in Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis - what is known and what is still unknown? Autoimmun Rev. 2020;19:102671.","journal-title":"Autoimmun Rev"},{"key":"3092_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/ndt\/gfm592","volume":"23","author":"T Yang","year":"2008","unstructured":"Yang T, Nast CC, Vo A, et al. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant. 2008;23:377\u201380.","journal-title":"Nephrol Dial Transplant"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03092-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03092-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03092-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T10:04:05Z","timestamp":1682503445000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03092-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3092"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03092-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1793330\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"25 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Medical Ethics Committee of Gansu Provincial Hospital, approval number [2022\u2009\u2212\u2009199] and the study was performed following the Declaration of Helsinki. Written informed consent was obtained from participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}